Analytical evaluation of eukaryotic cell-free translation (CFT) systems to assess mRNA translatability

mRNA vaccines constitute a promising new platform for infectious disease prevention, having demonstrated their efficacy in response to the COVID-19 pandemic. While mRNA attributes such as purity, integrity, 5'-capping, polyA tail length, and nucleobase lipidation are critical to vaccine efficacy, another key attribute of any vaccine mRNA is its translatability - that is, how much antigen protein is produced by ribosomal translation. To assess mRNA translatability, cell-free translation (CFT) can be employed. Advantages of CFT include its rapid readout (~5 hours), minimal sample consumption, and measurement of antigen translation directly from mRNA, thereby eliminating any variability associated with cell transfection efficiency. This is in contrast to cell-based methods, which require larger amounts of mRNA material and formulation in lipid nanoparticles or lipofectamine to facilitate cell transfection. When developing a CFT method to assay mRNA translatability, one key consideration is which CFT system to use as there are several commercially available systems from a variety of different organisms and cell types. Presented here is the evaluation of three eukaryotic CFT systems - wheat germ extract (WGE), rabbit reticulocyte lysate (RRL), and HeLa cell lysate (HCL) - for the purpose of developing an analytical method to assay the translatability of mRNA. The dynamic range, linear range, sensitivity to thermal stress, and sensitivity to potential impurities (e.g., EDTA, double-stranded RNA) were determined for each system. Although HCL translated less protein than either WGE or RRL systems, it showed several advantages, notably a larger linear range and greater sensitivity to mRNA thermal stress and dsRNA impurities. Therefore, while it is still worthwhile to screen different CFT systems, the results presented here suggest that HCL should be strongly considered when developing an analytical method to assay translatability for mRNA vaccines.